- Home
- ZBIO vs CRMD Comparison
ZBIO vs CRMD Comparison
Compare ZBIO & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZBIO
- CRMD
- Stock Information
- Founded
- ZBIO 2019
- CRMD 2006
- Country
- ZBIO United States
- CRMD United States
- Employees
- ZBIO N/A
- CRMD N/A
- Industry
- ZBIO
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- ZBIO
- CRMD Health Care
- Exchange
- ZBIO NYSE
- CRMD Nasdaq
- Market Cap
- ZBIO 389.2M
- CRMD 464.7M
- IPO Year
- ZBIO 2024
- CRMD 2010
- Fundamental
- Price
- ZBIO $9.81
- CRMD $8.50
- Analyst Decision
- ZBIO Strong Buy
- CRMD Strong Buy
- Analyst Count
- ZBIO 7
- CRMD 6
- Target Price
- ZBIO $32.29
- CRMD $14.50
- AVG Volume (30 Days)
- ZBIO 260.1K
- CRMD 2.6M
- Earning Date
- ZBIO 05-16-2025
- CRMD 05-08-2025
- Dividend Yield
- ZBIO N/A
- CRMD N/A
- EPS Growth
- ZBIO N/A
- CRMD N/A
- EPS
- ZBIO N/A
- CRMD N/A
- Revenue
- ZBIO $5,000,000.00
- CRMD $43,472,170.00
- Revenue This Year
- ZBIO N/A
- CRMD $207.65
- Revenue Next Year
- ZBIO N/A
- CRMD $50.13
- P/E Ratio
- ZBIO N/A
- CRMD N/A
- Revenue Growth
- ZBIO N/A
- CRMD N/A
- 52 Week Low
- ZBIO $5.83
- CRMD $3.61
- 52 Week High
- ZBIO $26.25
- CRMD $13.85
- Technical
- Relative Strength Index (RSI)
- ZBIO N/A
- CRMD 57.04
- Support Level
- ZBIO N/A
- CRMD $6.32
- Resistance Level
- ZBIO N/A
- CRMD $7.71
- Average True Range (ATR)
- ZBIO 0.00
- CRMD 0.49
- MACD
- ZBIO 0.00
- CRMD 0.32
- Stochastic Oscillator
- ZBIO 0.00
- CRMD 97.64
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.